Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2000

View Archived Issues

Roche highlights significant events in Q3 2000

Mother-to-child HIV transmission reduced by shorter, less expensive AZT treatment

Genentech updates product pipeline at investors conference

Gilead begins phase II studies with liposomal formulation of lurtotecan

Axonyx actively pursues development of AD treatments, diagnostics

Combination therapy including Maxamine proves effective and safe in chronic HCV

Clevudine phase I trial results presented at AASLD meeting

AASLD news: F-180 displays beneficial effects in portal hypertension-related bleeding

First clinical trial of EPI-2010 for asthma

Effects of Ono-8711, a selective EP1 receptor antagonist, on rat urinary bladder

Siga and Maxygen collaborate on development of novel vaccines

Fabrazyme advisory committee review not necessary

Relaxant effects of KRP-197 on human urinary bladder discussed at SIU congress

Botox provides sustained improvement to patients with drug-resistant detrusor hyperreflexia

Acorda awarded two NIH grants for CNS repair research

Degradation and stability of antitumor clinical candidate RH1 described at AAPS meeting

Idec files Zevalin BLA with FDA; European filing planned

Novel antitumor alkaloid CWJ-a-5: pharmacokinetics in rats

Single-dose rhIL-10 does not alter responses to allergen challenge in asthmatics

Preparation, activity and use of new cGMP-PDE inhibitors in cardiovascular and other disorders

New heterocyclic compounds from Shionogi with affinity for 5-HT receptors

Mitsubishi-Tokyo Pharmaceuticals reports synthesis and activity of imidazole M3 antagonists

SB researchers discover series of rodent anti-human IL-18 antibodies

Kinase-inhibitory indolinone compounds patented by Sugen

New MEK inhibitor from DuPont and its use in inflammation and cancer

Takeda's new GnRH antagonists, their production and use

New Knoll compound useful for seizures, neurological disorders and neurological damage

Antiviral agents for hepatitis emerge from R&D at CSIRO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...